Cargando…

Use of Non-Steroidal Anti-Inflammatory Drugs That Elevate Cardiovascular Risk: An Examination of Sales and Essential Medicines Lists in Low-, Middle-, and High-Income Countries

BACKGROUND: Certain non-steroidal anti-inflammatory drugs (NSAIDs) (e.g., rofecoxib [Vioxx]) increase the risk of heart attack and stroke and should be avoided in patients at high risk of cardiovascular events. Rates of cardiovascular disease are high and rising in many low- and middle-income countr...

Descripción completa

Detalles Bibliográficos
Autores principales:	McGettigan, Patricia, Henry, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3570554/ https://www.ncbi.nlm.nih.gov/pubmed/23424288 http://dx.doi.org/10.1371/journal.pmed.1001388

Ejemplares similares

Cardiovascular Risk with Non-Steroidal Anti-Inflammatory Drugs: Systematic Review of Population-Based Controlled Observational Studies
por: McGettigan, Patricia, et al.
Publicado: (2011)

Use of Fixed Dose Combination (FDC) Drugs in India: Central Regulatory Approval and Sales of FDCs Containing Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Metformin, or Psychotropic Drugs
por: McGettigan, Patricia, et al.
Publicado: (2015)

Systemic antibiotic sales and WHO recommendations, India
por: Mehta, Aashna, et al.
Publicado: (2022)

Selection of Essential Medicines for Diabetes in Low and Middle Income Countries: A Survey of 32 National Essential Medicines Lists
por: Bazargani, Yaser T., et al.
Publicado: (2014)

Selection of essential medicines for the prevention and treatment of cardiovascular diseases in low and middle income countries
por: Bazargani, Y. T., et al.
Publicado: (2018)

Essential medicines for breast cancer in low and middle income countries
por: Bazargani, Y. T., et al.
Publicado: (2015)

Availability of cytotoxic medicines in the WHO essential medicine list used in treating childhood malignancies in low-income and lower-middle-income countries: a systematic review protocol
por: Seneviwickrama, Maheeka, et al.
Publicado: (2023)

The availability of essential medicines for cardiovascular diseases at healthcare facilities in low- and middle-income countries: The case of Bangladesh
por: Hakim, Shariful, et al.
Publicado: (2022)

Comparison of essential medicines lists in 137 countries
por: Persaud, Nav, et al.
Publicado: (2019)

Availability and affordability of medicines and cardiovascular outcomes in 21 high-income, middle-income and low-income countries
por: Chow, Clara Kayei, et al.
Publicado: (2020)

Access to Cardiovascular Disease and Hypertension Medicines in Developing Countries: An Analysis of Essential Medicine Lists, Price, Availability, and Affordability
por: Husain, Muhammad Jami, et al.
Publicado: (2020)

Factors associated with the availability and affordability of essential cardiovascular disease medicines in low- and middle-income countries: A systematic review
por: Lotfizadeh, Ali, et al.
Publicado: (2022)

Withdrawn medicines included in the essential medicines lists of 136 countries
por: Charles, Onella, et al.
Publicado: (2019)

Access to cardiovascular medicines in low- and middle-income countries: a mini review
por: Harrison, Mark Amankwa, et al.
Publicado: (2023)

Barriers and Opportunities for Use of Patient Registries in Medicines Regulation
por: Olmo, Carla Alonso, et al.
Publicado: (2019)

Assessing variation among the national essential medicines lists of 21 high-income countries: a cross-sectional study
por: Taglione, Michael Sergio, et al.
Publicado: (2021)

Essential tuberculosis medicines and health outcomes in countries with a national essential medicines list
por: Maraj, Darshanand, et al.
Publicado: (2022)

A quantitative comparison of essential cardiovascular medicines from countries in the Southern African Development Community to the WHO model essential medicines list
por: Naicker, Ian, et al.
Publicado: (2022)

The availability, cost, and affordability of essential medicines for asthma and COPD in low-income and middle-income countries: a systematic review
por: Stolbrink, Marie, et al.
Publicado: (2022)

The Availability, Pricing, and Affordability of Essential Diabetes Medicines in 17 Low-, Middle-, and High-Income Countries
por: Babar, Zaheer-Ud-Din, et al.
Publicado: (2019)

Essential Medicines in a High Income Country: Essential to Whom?
por: Duong, Mai, et al.
Publicado: (2015)

Not just a number: examining coverage and content of antenatal care in low-income and middle-income countries
por: Benova, Lenka, et al.
Publicado: (2018)

Soft drink prices, sales, body mass index and diabetes: Evidence from a panel of low-, middle- and high-income countries
por: Goryakin, Yevgeniy, et al.
Publicado: (2017)

Correction to: Access to Cardiovascular Disease and Hypertension Medicines in Developing Countries: An Analysis of Essential Medicine Lists, Price, Availability, and Affordability
Publicado: (2020)

Interprofessional training for final year healthcare students: a mixed methods evaluation of the impact on ward staff and students of a two-week placement and of factors affecting sustainability
por: McGettigan, Patricia, et al.
Publicado: (2015)

Dabrafenib: A New Therapy for Use in BRAF-Mutated Metastatic Melanoma
por: McGettigan, Suzanne
Publicado: (2014)

The social life of voices: studying the neural bases for the expression and perception of the self and others during spoken communication
por: McGettigan, Carolyn
Publicado: (2015)

Availability, prices, and affordability of selected essential cancer medicines in a middle-income country – the case of Mexico
por: Moye-Holz, Daniela, et al.
Publicado: (2020)

Dexamethasone and COVID-19: Strategies in Low- and Middle-Income Countries to Tackle Steroid-Related Strongyloides Hyperinfection
por: Olivera, Mario J.
Publicado: (2021)

Assessing the impact of law enforcement to reduce over-the-counter (OTC) sales of antibiotics in low- and middle-income countries; a systematic literature review
por: Jacobs, Tom G., et al.
Publicado: (2019)

Essential packages of health services in low-income and lower-middle-income countries: what have we learnt?
por: Alwan, Ala, et al.
Publicado: (2023)

Confronting system barriers for ST- elevation MI in low and middle income countries with a focus on India
por: Mehta, Sameer, et al.
Publicado: (2018)

Examining the correlates and drivers of human population distributions across low- and middle-income countries
por: Nieves, Jeremiah J., et al.
Publicado: (2017)

Essential Occupational Safety and Health Interventions for Low- and Middle-income Countries: An Overview of the Evidence
por: Verbeek, Jos, et al.
Publicado: (2013)

Medication Adherence Interventions for Cardiovascular Disease in Low- and Middle-Income Countries: A Systematic Review
por: Ogungbe, Oluwabunmi, et al.
Publicado: (2021)

The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011–2018
por: Schuster Bruce, Catherine, et al.
Publicado: (2019)

Controlling cardiovascular diseases in low and middle income countries by placing proof in pragmatism
por: Owolabi, Mayowa, et al.
Publicado: (2016)

Availability of essential diagnostics in ten low-income and middle-income countries: results from national health facility surveys
por: Yadav, Harika, et al.
Publicado: (2021)

Dementia in low- and middle-income countries
por: Graham, Nori
Publicado: (2006)

Cost effective interventions for the prevention of cardiovascular disease in low and middle income countries: a systematic review
por: Shroufi, Amir, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_dfl59sdbntd1vn1bp445p1uo9o